标题/作者	年份
Fundamental mechanisms of immune checkpoint blockade therapy SC Wei, CR Duffy, JP Allison Cancer discovery 8 (9), 1069-1086	2018
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy JJ Havel, D Chowell, TA Chan Nature Reviews Cancer 19 (3), 133-150	2019
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic TA Chan, M Yarchoan, E Jaffee, C Swanton, SA Quezada, A Stenzinger, ... Annals of Oncology 30 (1), 44-56	2019
Cancer immunoediting and resistance to T cell-based immunotherapy JS O’Donnell, MWL Teng, MJ Smyth Nature reviews Clinical oncology 16 (3), 151-167	2019
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma TF Cloughesy, AY Mochizuki, JR Orpilla, W Hugo, AH Lee, TB Davidson, ... Nature medicine 25 (3), 477-486	2019
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications Y Zhang, Z Zhang Cellular & molecular immunology 17 (8), 807-821	2020
Tumour-intrinsic resistance to immune checkpoint blockade A Kalbasi, A Ribas Nature Reviews Immunology 20 (1), 25-39	2020
Systemic therapy for locally advanced and metastatic non–small cell lung cancer: a review KC Arbour, GJ Riely Jama 322 (8), 764-774	2019
Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance S Bagchi, R Yuan, EG Engleman Annual Review of Pathology: Mechanisms of Disease 16, 223-249	2021
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers M Chalabi, LF Fanchi, KK Dijkstra, JG Van den Berg, AG Aalbers, ... Nature medicine 26 (4), 566-576	2020
The lung microenvironment: an important regulator of tumour growth and metastasis NK Altorki, GJ Markowitz, D Gao, JL Port, A Saxena, B Stiles, T McGraw, ... Nature Reviews Cancer 19 (1), 9-31	2019
Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164 DT Le, TW Kim, E Van Cutsem, R Geva, D Jäger, H Hara, M Burge, ... Journal of Clinical Oncology 38 (1), 11	2020
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma RN Amaria, SM Reddy, HA Tawbi, MA Davies, MI Ross, IC Glitza, ... Nature medicine 24 (11), 1649-1654	2018
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial L Voorwerk, M Slagter, HM Horlings, K Sikorska, KK van de Vijver, ... Nature medicine 25 (6), 920-928	2019
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma CU Blank, EA Rozeman, LF Fanchi, K Sikorska, B van de Wiel, ... Nature medicine 24 (11), 1655-1661	2018
Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis Y Wang, S Zhou, F Yang, X Qi, X Wang, X Guan, C Shen, N Duma, ... JAMA oncology 5 (7), 1008-1019	2019
Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer PM Forde, J Spicer, S Lu, M Provencio, T Mitsudomi, MM Awad, E Felip, ... New England Journal of Medicine 386 (21), 1973-1985	2022
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions PY Wen, M Weller, EQ Lee, BM Alexander, JS Barnholtz-Sloan, ... Neuro-oncology 22 (8), 1073-1113	2020
Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study A Necchi, A Anichini, D Raggi, A Briganti, S Massa, R Lucianò, ... Journal of Clinical Oncology 36 (34), 3353-3360	2018
Neoadjuvant checkpoint blockade for cancer immunotherapy SL Topalian, JM Taube, DM Pardoll Science 367 (6477), eaax0182	2020

1 - 20

计算机程序会自动估算并确定日期和引用次数。